Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421378 | 0.91 | BCL9 (0.53) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL572371 | 0.90 | LMNA (0.59) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL28401460 | 0.89 | LMNA (0.54) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL7980728 | 0.87 | LMNA (0.65) | LMNAGAAKMT2AACHEMAPT | |
| SCHEMBL9736780 | 0.87 | LMNA (0.65) | LMNAGAAKMT2AACHEMAPT | |
| SCHEMBL30125136 | 0.87 | KMT2A (0.57) | LMNAGAAKMT2AALDH1A1 | |
| SCHEMBL28008331 | 0.87 | KMT2A (0.57) | LMNAGAAKMT2AALDH1A1 | |
| SCHEMBL8430064 | 0.87 | KMT2A (0.57) | LMNAGAAKMT2AALDH1A1 | |
| SCHEMBL30680466 | 0.87 | KMT2A (0.57) | LMNAGAAKMT2AALDH1A1 | |
| SCHEMBL28008648 | 0.87 | KMT2A (0.57) | LMNAGAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103025327-A | Oral iron deficiency therapy | EMISPHERE TECH INC | 2013-04-03 | — | — | CN | claimed |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| CN-107004768-B | Organic semiconductor composition containing a liquid medium | 巴斯夫欧洲公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-104144931-B | Pyrimido [4,5 b] indole derivatives and its application in the amplification of candidate stem cell | 蒙特利尔大学 | 2018-04-10 | — | — | CN | disclosed |
| CN-103025327-A | Oral iron deficiency therapy | EMISPHERE TECH INC | 2013-04-03 | — | — | CN | disclosed |
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2316831-A1 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20040067983-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1037881-B1 | PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES | AMGEN INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1037881-A1 | PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES | Amgen Inc. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999028303-A1 | PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES | AMGEN, INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067983-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | LMNA 4772/4885GAA 4039/4885KMT2A 4002/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | LMNA 2575/4885GAA 1464/4885KMT2A 4045/4885 |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | BCR, PDCD1LG2, PRLHR | LMNA 4012/4885GAA 3029/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.